NetworkNewsWire Announces Publication Discussing M&A Activity Driven by the Convergence of Cannabis and Medicine

November 09, 2017 8:30 AM EST | Source: NetworkNewsWire

New York, New York--(Newsfile Corp. - November 9, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.

The publication, titled, "Biotech M&A Momentum Attractive for Cannabinoid R&D Space," highlights biotech companies adding new innovations to the mounting number of therapeutic applications of cannabinoid.

To view the full publication, visit: https://www.networknewswire.com/biotech-ma-momentum-attractive-cannabinoid-rd-space/

"Global pharma and life sciences M&A values slumped over 60 percent in Q3 of this year, as compared to Q2, in all subsectors except biotech, according to Pricewaterhouse Coopers. Large companies losing revenue amid expiring patents and facing costly R&D is a pattern baked into the biotech market. As such, the acquisition of revenue-producing biotechs as a solution is a trend that will most likely hold fast in upcoming years. Such a robust, underlying market environment is great news for cannabinoid biosynthesis pioneer InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), the developer of a proprietary, scalable biosynthesis process capable of manufacturing all of the more than 90 naturally-occurring cannabinoids at pharmaceutical grades in-house - a rare and possibly unattained ability for everyone else in the industry. What this means is that InMed provides a solution to a main hindrance of U.S. FDA approval of cannabinoid-based therapies: producing consistent, pharmaceutical-grade cannabinoids that are identical to those found in nature.

"This capability also enables InMed to cost-effectively produce its own high-yield cannabinoids for its product pipeline, rather than outsourcing cultivation as does industry giant GW Pharmaceuticals and other cannabis-focused biotechs. InMed's lead product, INM-750 (http://nnw.fm/0Q5ia), is a topical product designed to treat epidermolysis bullosa (EB), a rare disease of the skin's connective tissues, for which there is a significant unmet medical need and no currently approved treatments. INM-750 contains a combination of biosynthetically-produced cannabinoids carefully selected to modulate levels of the key keratins (proteins) that are absent in EB patients and, thereby, it is hoped, modulate the disease itself. INM-750 is also designed to address the numerous symptoms of EB such as inflammation, wound healing, skin regeneration, itching, and pain."

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.

For more information, visit www.InMedPharma.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

NNW Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

info